1. Phillyrin lowers body weight in obese mice via the modulation of PPAR<beta>/<delta>-ANGPTL 4 pathway.
- Author
-
Xiao HB, Sui GG, and Lu XY
- Subjects
- Angiopoietins genetics, Animals, Disease Models, Animal, Mice, Mice, Inbred C57BL, Mice, Obese, Obesity metabolism, PPAR alpha genetics, Angiopoietins biosynthesis, Glucosides pharmacology, Obesity drug therapy, PPAR alpha biosynthesis, Signal Transduction drug effects
- Abstract
Objective: Previous investigations have shown that the peroxisome proliferator activated receptor beta/delta (PPAR
/ )-angiopoietin-like protein 4 (ANGPTL4) pathways may be a new pharmacologic target for treatment of obesity. The present study was conducted to test the effect of phillyrin, a glucoside, on obesity in mice., Method: Fifty mice were randomly divided into 5 groups (n=10): control group (C57BL/6J mice), obese mice group, two groups of obese mice treated with phillyrin (15 or 45mg/kg/day), one group of obese mice treated with PPAR / agonist GW0742 (3mg/kg/day). Twelve weeks after treatment, body weight, liver weight, fat weight, lipid levels in the liver, serum levels of tumour necrosis factor- (TNF- ), leptin, and insulin, expression of PPAR / , ANGPTL4, and AMP-activated protein kinase (AMPK) were determined., Results: Treatment with phillyrin (15 or 45mg/kg) significantly decreased body weight, liver weight, fat weight, hepatic total cholesterol, free fatty acid, and triglyceride concentrations, serum levels of TNF- , leptin, and insulin concomitantly with up-regulated expression of PPAR / , ANGPTL4, and p-AMPK- . In addition, GW0742 has similar effect of phillyrin., Conclusions: The present results suggest that phillyrin could regulate the PPAR / -ANGPTL 4 pathway to lower body weight in obese C57BL/6J mice., (Copyright © 2017 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.) - Published
- 2018
- Full Text
- View/download PDF